Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Other financing activities (2023)

Ptc Therapeutics has reported Other financing activities over the past 1 years, most recently at $85000.0 for Q3 2023.

  • Quarterly results put Other financing activities at $85000.0 for Q3 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was $282000.0 (changed N/A YoY), and the annual figure for FY2023 was $282000.0, down 97.54%.
  • Other financing activities for Q3 2023 was $85000.0 at Ptc Therapeutics, up from $15000.0 in the prior quarter.
  • Over the last five years, Other financing activities for PTCT hit a ceiling of $182000.0 in Q1 2023 and a floor of $15000.0 in Q2 2023.